Open Access
Issue
J Extra Corpor Technol
Volume 56, Number 3, September 2024
Page(s) 125 - 127
DOI https://doi.org/10.1051/ject/2024021
Published online 20 September 2024
  1. Azaad MA, Quirong Z, Yongping Li. Factor XII (Hageman factor) deficiency: a very rare coagulation disorder. Open J Blood Dis. 2015;5(4):39–42. [CrossRef] [Google Scholar]
  2. Caen J, Wu Q. Hageman factor, platelets and polyphosphates: early history and recent connection. J Thromb Hemost. 2010;8(8):1670–1674. [CrossRef] [Google Scholar]
  3. Conaglen PJ, Akowuah E, Sanjay T, Atkinson V. Implications for cardiac surgery in patients with factor XII deficiency. Ann Thorac Surg. 2010;89(2):625–626. [CrossRef] [PubMed] [Google Scholar]
  4. Schmaier A. The elusive physiologic role of factor XII. J Clin Invest. 2008;118(9):3006–3009. [PubMed] [Google Scholar]
  5. Andrew M, Patsy V, Johnston M, et al. Maturation of the hemostatic system during childhood. Blood. 1992;80(8):1998–2005. [CrossRef] [PubMed] [Google Scholar]
  6. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood. 1987;70(1):165–172. [CrossRef] [PubMed] [Google Scholar]
  7. Hanmod S, Jesudas R, Kulkarni R, Chitlur M. Neonatal hemostatic disorders: issues and challenges. Semin Thromb Hemost. 2016;42(7):741–751. https://doi.org/10.1055/s-0036-1593415. [CrossRef] [PubMed] [Google Scholar]
  8. Chaudhry LA, El-Sadek WYM, Chaudhry GA, et al. Factor XII (Hageman factor) deficiency: a rare harbinger of life threatening complications. Pan Afr Med J. 2019;33:39. [CrossRef] [PubMed] [Google Scholar]
  9. Halbmayer WM, Haushofer A, Schön R, et al. The prevalence of moderate and severe FXII (Hageman factor) deficiency among the normal population: evaluation of the incidence of FXII deficiency among 300 healthy blood donors. Throm Haemost. 1994;71(1):068–072. [CrossRef] [Google Scholar]
  10. Gerhardt MA, Greenberg CD, Slaughter TF, et al. Factor XII deficiency and cardiopulmonary bypass: use of a novel modification of the activated clotting time to monitor anticoagulation. Anesthesiology. 1997;87:990–992. [CrossRef] [PubMed] [Google Scholar]
  11. Erkinaro T, Moilanen J, Lahtinen J, et al. The standard point-of-care Hemochron Jr. ACT + test in monitoring heparin administration for cardiopulmonary bypass in severe factor XII deficiency. J Cardiothorac Vasc Anesth. 2022;36(7):2031–2034. [CrossRef] [PubMed] [Google Scholar]
  12. Regling K, Ramiz S, Chitlur MB. Factor XII deficiency in ECMO patients. Blood. 2019;134(1):4965. [CrossRef] [Google Scholar]
  13. De Vries A, Lansink-Hartgring AO, Fernhout FJ, et al. Activated clotting time in cardiac surgery: should Celite or kaolin be used? Interact CardioVasc Thorac Surg. 2017;24(4):549–554. [PubMed] [Google Scholar]
  14. Uppal V, Rosin M. Factor XII deficiency and cardiopulmonary bypass. J Extra Corpor Technol. 2014;46(3):254–257. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  15. Cronbaugh RD, Fuller LA, Miller SD, et al. Cardiopulmonary bypass in a patient with factor XII deficiency. J Extra Corpor Technol. 2014;46(3):251–253. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  16. Stelmach P, Nowak W, Robak M, Krzemińska E, Tybura-Sawicka M, Chojnowski K, Treliński J. In seeking diagnostic tool for laboratory monitoring of FXII-targeting agents, could assessment of rotational thromboelastometry (rotem) in patients with factor XII deficiency be useful? Acta Haematol Polon. 2022;53(4):267–272. https://doi.org/10.5603/ahp.a2022.0034. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.